BRÈVE

sur Rentschler Biopharma SE

Rentschler Biopharma Announces Executive Changes and Strategic Phase

Rentschler Biopharma SE, a prominent player in biopharmaceutical contract development and manufacturing, announced executive changes as it enters a new strategic phase. Uwe Buecheler, PhD, Vice Chairman of the Supervisory Board, steps in as interim CEO. This follows a mutual decision for CEO Benedikt von Braunmuehl to step down. The shift aims to bolster long-term growth and value.

Christiane Bardroff, Chief Operating Officer, is also leaving for new opportunities. Her successor is pending announcement. During her tenure, she spearheaded operational advancements, notably increasing production at the Milford and Laupheim sites.

Buecheler emphasizes client satisfaction and business expansion, working closely with the CFO and incoming COO. With over 30 years in the industry, his focus remains on advancing Rentschler Biopharma's mission of quality and reliable partnership.

R. H.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Rentschler Biopharma SE